If you are currently receiving prophylactic heme treatment and are interested in participating in the ongoing Panhematin® Prevention Study, please contact Edrin Williams, Director of Patient Services for more information (email: email@example.com phone: 301.347.7166). This research study is important for physicians to better understand the benefits of prophylactic heme treatment.
Inclusion criteria for the Panhematin® Prevention Study:
• Need to have well-diagnosed and documented AIP/HCP or VP with lab results
• Had previous attacks of porphyria with symptoms such as abdominal pain, back or limb pain.
• Currently on a regimen of Panhematin® infusion to prevent acute attacks.
Travel to the study site is included.